Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 5.93
- Piotroski Score 5.00
- Grade Overweight
- Symbol (CTKB)
- Company Cytek Biosciences, Inc.
- Price $6.39
- Changes Percentage (-5.74%)
- Change -$0.39
- Day Low $6.34
- Day High $6.78
- Year High $9.87
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $8.50
- High Stock Price Target $8.50
- Low Stock Price Target $8.50
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.09
- Trailing P/E Ratio -66.67
- Forward P/E Ratio -66.67
- P/E Growth -66.67
- Net Income $-12,148,000
Income Statement
Quarterly
Annual
Latest News of CTKB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Cytek Biosciences Inc (CTKB) Q3 2024 Earnings Call Highlights: Revenue Growth and Positive Net ...
The CEO discusses the normalized demand environment in the US, emphasizing the essential role of flow cytometry in biology labs. The CFO expects sequential revenue growth in Q4 and outlines strategies...
By Yahoo! Finance | 1 week ago -
Cytek Biosciences, Inc. (NASDAQ:CTKB) is a favorite amongst institutional investors who own 51%
Ownership research and analyst forecasts provide insights into stock opportunities. Institutional investors own 51% of Cytek Biosciences, impacting its market moves. Top shareholders include BlackRock...
By Yahoo! Finance | 3 months ago
